- Home
- COMM vs ORKA Comparison
COMM vs ORKA Comparison
Compare COMM & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COMM
- ORKA
- Stock Information
- Founded
- COMM 1976
- ORKA 2004
- Country
- COMM United States
- ORKA United States
- Employees
- COMM N/A
- ORKA N/A
- Industry
- COMM Radio And Television Broadcasting And Communications Equipment
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- COMM Technology
- ORKA Health Care
- Exchange
- COMM Nasdaq
- ORKA Nasdaq
- Market Cap
- COMM 3.6B
- ORKA 580.3M
- IPO Year
- COMM 2013
- ORKA N/A
- Fundamental
- Price
- COMM $16.65
- ORKA $15.26
- Analyst Decision
- COMM Hold
- ORKA Strong Buy
- Analyst Count
- COMM 5
- ORKA 8
- Target Price
- COMM $12.38
- ORKA $40.43
- AVG Volume (30 Days)
- COMM 5.7M
- ORKA 133.8K
- Earning Date
- COMM 11-06-2025
- ORKA 11-12-2025
- Dividend Yield
- COMM N/A
- ORKA N/A
- EPS Growth
- COMM N/A
- ORKA N/A
- EPS
- COMM 3.34
- ORKA N/A
- Revenue
- COMM $4,751,500,000.00
- ORKA N/A
- Revenue This Year
- COMM $27.35
- ORKA N/A
- Revenue Next Year
- COMM $9.07
- ORKA N/A
- P/E Ratio
- COMM $4.96
- ORKA N/A
- Revenue Growth
- COMM 20.87
- ORKA N/A
- 52 Week Low
- COMM $2.94
- ORKA $5.49
- 52 Week High
- COMM $16.83
- ORKA $31.13
- Technical
- Relative Strength Index (RSI)
- COMM 70.96
- ORKA 51.26
- Support Level
- COMM $16.04
- ORKA $15.23
- Resistance Level
- COMM $16.83
- ORKA $16.21
- Average True Range (ATR)
- COMM 0.58
- ORKA 0.94
- MACD
- COMM -0.21
- ORKA -0.04
- Stochastic Oscillator
- COMM 89.02
- ORKA 36.22
About COMM CommScope Holding Company Inc.
CommScope Holding Co Inc is a provider of infrastructure solutions for communication, data center, and entertainment networks. The company provides solutions for wired and wireless networks to enable service providers, including cable, telephone, data center, and digital broadcast satellite operators and media programmers, to deliver media, voice, Internet Protocol (IP) data services, and Wi-Fi to their subscribers and allow enterprises to experience constant wireless and wired connectivity across complex and varied networking environments. The company's operating segments are: Connectivity and Cable Solutions (CCS), Networking, Intelligent Cellular and Security Solutions (NICS), and Access Network Solutions (ANS).
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.